VYNE Therapeutics (VYNE) Competitors $0.35 +0.00 (+0.26%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.06%) As of 08/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE vs. ELEV, AYTU, BCAB, ADAP, MBRX, CASI, QTTB, FNCH, PASG, and RVPHShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Elevation Oncology (ELEV), Aytu BioPharma (AYTU), BioAtla (BCAB), Adaptimmune Therapeutics (ADAP), Moleculin Biotech (MBRX), CASI Pharmaceuticals (CASI), Q32 Bio (QTTB), Finch Therapeutics Group (FNCH), Passage Bio (PASG), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Its Competitors Elevation Oncology Aytu BioPharma BioAtla Adaptimmune Therapeutics Moleculin Biotech CASI Pharmaceuticals Q32 Bio Finch Therapeutics Group Passage Bio Reviva Pharmaceuticals Elevation Oncology (NASDAQ:ELEV) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Do institutionals & insiders have more ownership in ELEV or VYNE? 83.7% of Elevation Oncology shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 8.1% of Elevation Oncology shares are owned by insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to ELEV or VYNE? In the previous week, VYNE Therapeutics had 8 more articles in the media than Elevation Oncology. MarketBeat recorded 8 mentions for VYNE Therapeutics and 0 mentions for Elevation Oncology. VYNE Therapeutics' average media sentiment score of 0.23 beat Elevation Oncology's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Elevation Oncology Neutral VYNE Therapeutics Neutral Which has better earnings and valuation, ELEV or VYNE? VYNE Therapeutics has higher revenue and earnings than Elevation Oncology. Elevation Oncology is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElevation OncologyN/AN/A-$44.49M-$0.82-0.45VYNE Therapeutics$500K10.67-$39.83M-$0.99-0.35 Is ELEV or VYNE more profitable? Elevation Oncology has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -8,097.69%. VYNE Therapeutics' return on equity of -72.34% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Elevation OncologyN/A -74.68% -48.14% VYNE Therapeutics -8,097.69%-72.34%-57.92% Which has more risk & volatility, ELEV or VYNE? Elevation Oncology has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Do analysts recommend ELEV or VYNE? Elevation Oncology currently has a consensus price target of $2.62, indicating a potential upside of 616.89%. VYNE Therapeutics has a consensus price target of $6.25, indicating a potential upside of 1,681.64%. Given VYNE Therapeutics' higher possible upside, analysts plainly believe VYNE Therapeutics is more favorable than Elevation Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elevation Oncology 0 Sell rating(s) 11 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00VYNE Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryVYNE Therapeutics beats Elevation Oncology on 9 of the 13 factors compared between the two stocks. Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.32M$2.75B$5.67B$9.82BDividend YieldN/A1.77%3.79%4.07%P/E Ratio-0.3921.8930.5825.12Price / Sales10.67740.48464.45115.80Price / CashN/A177.1637.4059.05Price / Book0.105.079.096.18Net Income-$39.83M$31.61M$3.25B$264.89M7 Day Performance-1.71%25.12%7.32%4.18%1 Month Performance-72.16%3.84%5.42%1.99%1 Year Performance-81.14%10.43%30.66%24.22% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics2.1865 of 5 stars$0.35+0.3%$6.25+1,681.6%-81.1%$5.32M$500K-0.3930News CoverageEarnings ReportShort Interest ↑ELEVElevation Oncology1.3707 of 5 stars$0.37flat$2.62+616.9%N/A$21.62MN/A-0.4540AYTUAytu BioPharma3.7852 of 5 stars$2.24-5.5%$10.00+346.4%-14.9%$21.27M$81M-3.11160News CoverageBCABBioAtla2.3292 of 5 stars$0.36+2.8%$5.00+1,279.3%-80.4%$20.60M$11M-0.3360News CoverageAnalyst DowngradeAnalyst RevisionADAPAdaptimmune Therapeutics1.8979 of 5 stars$0.09+10.7%$1.35+1,475.4%-94.5%$20.54M$178.03M-0.32490News CoverageEarnings ReportShort Interest ↑Analyst RevisionGap DownMBRXMoleculin Biotech2.7931 of 5 stars$0.62-7.8%$4.00+543.1%-69.4%$20.38MN/A0.0020News CoverageEarnings ReportAnalyst RevisionCASICASI Pharmaceuticals4.0897 of 5 stars$1.73+6.1%$4.00+131.2%-63.7%$20.05M$28.54M-0.68180QTTBQ32 Bio2.7691 of 5 stars$1.79+9.8%$12.17+579.7%-94.6%$19.88M$1.16M-0.4239News CoverageShort Interest ↓FNCHFinch Therapeutics GroupN/A$12.24-1.6%N/A+5.7%$19.66MN/A-1.39190PASGPassage Bio3.8006 of 5 stars$5.90-5.9%$150.00+2,442.4%-55.4%$19.56MN/A-0.29130News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionRVPHReviva Pharmaceuticals2.9476 of 5 stars$0.45+9.9%$9.00+1,911.2%-21.2%$19.54MN/A-0.575News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap Up Related Companies and Tools Related Companies ELEV Competitors AYTU Competitors BCAB Competitors ADAP Competitors MBRX Competitors CASI Competitors QTTB Competitors FNCH Competitors PASG Competitors RVPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYNE) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access